ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2099

Elderly – Onset Sarcoidosis: a Single Center Comparative Study

Senol Kobak1, Fidan Yildiz2, Huseyin Semiz3 and Mehmet Orman4, 1Rheumatology, Istinye University Faculty of Medicine, Istanbul, Turkey, 2Chest Diseases, Medicalpark Hospital, İzmir, Turkey, 3Internal Medicine, Ege University Faculty of Medicine, İzmir, Turkey, 4Statistics, Ege University Faculty of Medicine, İzmir, Turkey

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: sarcoidosis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Sarcoidosis is a chronic granulomatous inflamatory disease characterized with non-caseified granuloma formation. It is rarely affects patients older than 65 years old..The purpose of this study is to compare and evaluate the demografic, clinical and laboratory features of elderly-onset(EOS) and young-onset sarcoidosis(YOS) patients.

Methods:

One hundred and thirty one patients diagnosed with sarcoidosis according to clinical, radiologic and histopathological evaluation were included in this study.The patients with initial symptoms started after age 65 were accepted as EOS. Demografic, clinic, radiologic, and laboratory data and the medication which the patients recieved were recorded and retrospectively evaluated.

Results:

Twenty(15.3%)of 131 patients were diagnosed as EOS, and 111(84.7%) patients were evaluated as YOS. Fifteen of 20 EOS patients were female and 5 of them were male. Average duration of the disease was determined as 38.4months for YOS and 22.5months for EOS(p=0.556).Delay of the diagnosis was 12months for YOS while it was 3months for EOS(p=0.001).Higher rates of fatique, comorbid diseases and more Hydroxychloroquine(HQ) use were detected in EOS patients comparing to YOS(p=0.010, p=0.003 and p=0.039 respectively).There was obviously more disease modifying anti-rheumatic drugs(DMARDs) use by YOS group but statistical difference wasn’t significant. The 3-year survival rate after diagnosis of sarcoidosis was %95 in the EOS group, compared with %100 in the YOS group

Conclusion:

In this study we showed that YOS and EOS patients may be presented with different clinical, and laboratory features. EOS patients are characterized with higher rates of fatique and comorbid diseases, less inflammatory sign and delayed diagnosis, and less DMARDs usage.


Disclosure: S. Kobak, None; F. Yildiz, None; H. Semiz, None; M. Orman, None.

To cite this abstract in AMA style:

Kobak S, Yildiz F, Semiz H, Orman M. Elderly – Onset Sarcoidosis: a Single Center Comparative Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/elderly-onset-sarcoidosis-a-single-center-comparative-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/elderly-onset-sarcoidosis-a-single-center-comparative-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology